An Oral Breakthrough in Autoimmunity
As of April 19, 2026, Sotyktu is approved for Psoriatic Arthritis (PsA). This first-in-class TYK2 inhibitor simplifies management for those whose metabolic health is complicated by chronic inflammation.
Strategic Data Expansion 2026.4
The TYK2 Advantage
Lower risk of cardiovascular 'major adverse events' (MACE) compared to JAK inhibitors. [Image showing the specific TYK2 signaling blockade] LSI keywords like 'selective TYK2 inhibition' are now key focus areas.
Selectivity Index
Inhibition Specificity
$$S_i = rac{IC_{50}( ext{JAK1})}{IC_{50}( ext{TYK2})}$$
Strategic Advice: If you have biologic burnout, ask your rheumatologist about the Sotyktu oral alternative.